Off-label use = uncontrolled variables Were seeing increasing use in populations: Outside licensed BMI thresholds Without comorbidity Without ongoing clinical monitoring This creates a perfect storm: Dose escalation without supervision Poor management of GI side effects No medication reconciliation (often overlooked) And this is where things start to get clinically interesting The hidden interaction risk: oral medications GLP-1s dont just act on appetite
Large meals can cause palpitations as the body redirects blood flow to support digestion, which can temporarily affect the heart rhythm
Koozehchian MS, Daneshfar A, Fallah E, Agha-Alinejad H, Samadi M, Kaviani M, Kaveh BM, Jung YP, Sablouei MH, Moradi N, et al
It has antioxidant and cellular protective properties that are getting much attention in medical circles
Szczegln uwag zwraca si rwnie na jego obecno w tkankach o wysokiej aktywnoci metabolicznej
The accumulated data indicate that mitochondria, mTOR, and autophagy may represent an integral regulatory axis during ASD [16, 251, 253, 308]
